hey tomn, it's funny - a cousin asked me last year to help her get started in the stock market - she wanted big returns, etc... I recommended CALA and INFI and a few months later she was ready to kill me... I explained capital gains, patience, etc....
At least she is now ahead on both and expecting to see a lot more - and she still loves me....
I don't have a huge position in INFI but moved several thousand shares into a Roth IRA last year at ~$1.50. My initial cost basis for all shares is ~$2.10...
yeah, I'm okay with where we stand for now and getting more optimistic - ystdy was HUGE for INFI and nice to see a small gain today on more than 3X volume. Still not sure about management - Adelene Perkins' salary is obscene... How is that justified??? Also not real comfortable with finances but was glad they went with BVF deal instead of issuing more shares. They may issue a secondary if share price gets into the $3-$4 range and hope they get bought before that happens.... as you say, they only need to show promising activity as a mono therapy in one indication to generate a lot of interest and a big move in price share. There are plenty of IO and VEGFR inhibitors that could be combined with IPI-549 for a really effective therapy...
see you around...